Latest Regulatory News

Galan Lithium's Hombre Muerto West project in Argentina has been approved for the government’s RIGI incentive regime, promising long-term fiscal benefits and operational certainty. This milestone strengthens the project's competitive edge as it approaches production.

Macarthur Minerals Limited’s MIOOB securities have been suspended from trading due to non-compliance with ASX listing rules, raising questions about the company’s regulatory standing.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.

Paterson Resources has secured heritage clearance and reported promising metallurgical results at its Grace Gold-Copper Project, setting the stage for a significant drilling campaign to upgrade its resource estimate.

Octava Minerals Limited has had its trading suspension lifted following the announcement of a proposed capital raising, signaling renewed market activity for the mining explorer.

Octava Minerals secures $1.5 million in a placement to fund exploration and due diligence for acquiring the historically promising Federation copper-zinc-silver project in Western Tasmania.

Orpheus Uranium has secured a Native Title Mining Agreement with the Wilyakali people, unlocking advanced exploration at its Radium Hill South and Mundaerno projects. This milestone sets the stage for drilling approvals expected by late 2025.

Venus Metals Corporation has secured the mining lease for its Bellchambers gold deposit, unlocking the path toward advancing development with promising drilling results and planned resource updates.

DeSoto Resources has ramped up exploration at its Northern Territory Spectrum Project, deploying a second drill rig and completing a significant deep hole at the Quantum Rare Earth Deposit.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Stockland updates its interim dividend for the six months ending June 2025, confirming an estimated payout of AUD 0.172 per security and announcing the Dividend Reinvestment Plan price at AUD 5.43 with a 1% discount.